Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials
Selecting patients for phase I cancer trials is crucial to ensure a sufficient life expectancy. Frail patients, better suited for palliative care, should not be exposed to new drugs with minimal benefit. Enrolling patients at high risk of early death can jeopardize the study. Our analysis of two large precision medicine studies used tumor fraction from ctDNA to develop a predictive model, demonstrating notable predictive accuracy and aiding in patient selection.
Authors
- Ludovic Lacroix (ORCID: https://orcid.org/0000-0003-2535-1010)
- Kilian Trin (ORCID: https://orcid.org/0000-0002-7650-645X)
- Mélissa Alamé
- Jean‐Charles Soria (ORCID: https://orcid.org/0000-0001-9597-0701)
- Etienne Rouleau (ORCID: https://orcid.org/0000-0002-6316-5668)
- Laïla Belcaid (ORCID: https://orcid.org/0000-0001-8062-1533)
- Carine Bellera (ORCID: https://orcid.org/0000-0001-7926-4671)
- Amandine Crombé (ORCID: https://orcid.org/0000-0003-0098-6482)
- Antoîne Italiano (ORCID: https://orcid.org/0000-0002-8540-5351)
- L. Blouin
- Arnaud Bayle (ORCID: https://orcid.org/0000-0002-2150-7906)
- Damien Vasseur (ORCID: https://orcid.org/0000-0001-8787-1498)
- Sophie Cousin (ORCID: https://orcid.org/0000-0002-4847-6329)
- Isabelle Soubeyran
- Simone Mathoulin‐Pélissier
Institutions
- Université de Bordeaux (FR)
- Inserm (FR)
- Institut Gustave Roussy (FR)
- Bordeaux Population Health (FR)
- Institut Bergonié (FR)
- Centre d'Investigation Clinique Plurithématique de Bordeaux
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1038/s41698-024-00685-9
- Citations
- 4
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 1.14
Funders
- Institut Gustave-Roussy
- Fondation Gustave Roussy